

COVID-19 Vaccine Workplace Programme Considerations



MANJURUL/GETTY IMAGES

Dr. Azwi Takalani

Public Health Medicine Specialist

Safety Physician on Sisonke: Open Label Trial

04 March 2021

Conflicts to declare

- Safety physician and Medical monitor in ongoing COVID-19 and HIV vaccine trials. Some trials are sponsored by industry.

Outline

- **Preparation Phase**

- National Roll – out Plan: Work based vaccination programmes
- Optimising COVID-19 vaccine coverage in the workplace


- **Operational Phase**

- Vaccine Scheduling
- Vaccine storage & distribution
- Adverse Event Following Immunisation Reporting





Preparation Phase

PHASED APPROACH FOR VACCINE INTRODUCTION




PHASE 2 AND 3: HIGH RISK PRIORITY GROUPS AND GENERAL PUBLIC SERVICE DELIVERY PLATFORMS





Employee Capacitation: Informed Decision Making



Vaccine Hesitancy Immunity

Vaccine Science

How vaccines work
Vaccine Development

Vaccine Efficacy

Per vaccine candidate
Continuance of NPI



Safety Profiles

Common reactogenicity profile
Contextualise serious adverse events

Regulatory Processes

Development and licensing processes

Managing Exemptions

- Medical Exemptions
 - Severe allergic reactions to vaccine constituents
- Religious Exemptions
 - Explore grounds is employee willing
- Choice
- Document vaccine offer; employee decision & contingency plan (if applicable)



Operational Phase

Vaccine Scheduling

- Vaccine scheduling - balance of optimising vaccine coverage vs operational needs
 - Staggered approach
 - Job category & shift mixing
- Reactogenicity profile
 - Days off post vaccination e.g. vaccinee develops fever
 - Two dose regimens

Vaccine storage & distribution

Product	Design	Adjuvant	Cold chain
Moderna mRNA-1273	mRNA	-	- 20 degreesC
AstraZeneca AZD1222	Chimp adenovirus vector	-	2 to 8 degreesC
Janssen Ad26.COVS.S	Human adenovirus-26 vector	-	2 to 8 degreesC
Novavax SARS-CoV-2 rS	Protein Subunit Nanoparticle	Matrix-M™	2 to 8 degreesC
Pfizer	mRNA	-	- 70 degreesC

- Reliable refrigerators/freezers
- Temperature monitoring devices
- Temperature excursion management protocols
- Vaccine inventory management systems
- Transportation

Adverse Event Following Immunisation Reporting



ALL VACCINES including COVID-19

CASE REPORTING FORM (CRF) FOR ADVERSE EVENTS FOLLOWING IMMUNISATION (AEFI)

EPID Number:

S	O	A	-																
---	---	---	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Country - Province - District - Year - Case no

Today's date: DD/MM/YYYY

All fields in this form are mandatory, unless indicated 'if applicable'. Provide the requested information or tick the appropriate box.

Date received	Level	Signature
	Private	
	District	
	Province	
	National EPI	
	National SAHPRA	

(For Office use only)

SECTION A: IDENTIFYING INFORMATION


NOTE: In maternal vaccination, if mother and baby / more than one baby are affected, complete separate form for each affected individual



Align reporting with AEFI requirements embedded in Expanded Programme on Immunisation



Currently paper based, electronic tool being developed



Thank you